Allergy Therapeutics (LON:AGY) Shares Down 5.3% - What's Next?

Allergy Therapeutics plc (LON:AGY - Get Free Report)'s stock price was down 5.3% on Tuesday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 7.10 ($0.10). Approximately 162,276 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 408,738 shares. The stock had previously closed at GBX 7.50 ($0.10).

Allergy Therapeutics Stock Performance

The business's 50 day moving average price is GBX 6.81 and its two-hundred day moving average price is GBX 6.63. The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63. The company has a market capitalization of £339.14 million, a price-to-earnings ratio of -6.65, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) EPS for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. Equities analysts forecast that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.